Abstract:"Intelligent" crosslinked nanoparticles (NPs) provide great advantages in enhancing drug bioavailability and reducing side effects in anticancer therapeutics. In this study, a novel biodegradable polyphosphoester-based functional copolymer prodrug PTX-(PBYP-g-MPA)-b-PEEP was prepared to construct pH/redox dual-responsive core-crosslinked nanoparticles (DOX/CCL NPs), in which paclitaxel (PTX) was conjugated to the polyphosphoester to form an amphiphilic prodrug and doxorubicin (DOX) was encapsulated inside the prodrug NPs. At first, PTX was used as an initiator to polymerize 2-(but-3-yn-1-yloxy)-2-oxo-1,3,2-dioxaphospholane (BYP) and 2-ethoxy-2-oxo-1,3,2-dioxaphospholane (EOP) by one-pot sequential ring-opening polymerization, yielding a biodegradable polymeric prodrug PTX-PBYP-b-PEEP. Subsequently, a radical-mediated thiol-yne "click" reaction was performed between the alkynyl groups on the PBYP segment and the thiol group of 3-mercaptopropionic acid (MPA) to form a functional carboxyl group at the side chain. The potential positively charged DOX·HCl can be physically encapsulated via electrostatic interaction with the carboxyl group and hydrophobic interaction. Afterwards, the DOX/CCL NPs with cleavable disulfide (S-S) linkages can be formed by partial crosslinking through amidation between the pendant carboxyl groups and cystamine. These NPs possess multifunctional characteristics used for in vitro drug release. Notably, a redox-responsive crosslinker, cystamine dihydrochloride, and synergetic non-covalent interactions not only stabilize the nanoparticles, achieve high DOX-loading capacity of drug loading content (DLC, 14.6%) and drug loading efficiency (DLE, 73.1%), but also endow the DOX/CCL NPs with controlled drug release capacity, which is due to the cleavage of S-S bonds in the presence of 10 mM glutathione (GSH) and weakened electrostatic interaction caused by the protonation of carboxyl groups at a lower pH (5.0). Moreover, these pH/redox dual-responsive DOX/CCL NPs can be steadily internalized by HeLa cells, exhibiting high-efficiency cellular proliferation inhibition. This study presents a promising strategy for controlled intracellular drug release in cancer therapy.

Ph-Responsive Core-Shell Structured Nanoparticles for Triple-Stage Targeted Delivery of Doxorubicin to Tumors

Core–shell structured nanospheres for photothermal ablation and pH-triggered drug delivery toward synergistic cancer therapy

Surface charge-reversible polyelectrolyte complex nanoparticles for hepatoma-targeting delivery of doxorubicin.

Zwitterionic Nanoparticles Constructed with Well-Defined Reduction-Responsive Shell and Ph-Sensitive Core for “spatiotemporally Pinpointed” Drug Delivery

Synthesis and in Vitro Characterization of Carboxymethyl Chitosan-CBA-Doxorubicin Conjugate Nanoparticles As Ph-Sensitive Drug Delivery Systems

Programmed Ph/reduction-Responsive Nanoparticles for Efficient Delivery of Antitumor Agents in Vivo.

Enhanced Cellular Internalization and On-Demand Intracellular Release of Doxorubicin by Stepwise Ph-/Reduction-responsive Nanoparticles.

Facile Preparation of Core Cross-Linked Nanomicelles Based on Graft Copolymers with Ph Responsivity and Reduction Sensitivity for Doxorubicin Delivery.

Stepwise Ph-Responsive Nanoparticles for Enhanced Cellular Uptake and On-Demand Intracellular Release of Doxorubicin

Ph-Sensitive Chitosan-Derived Nanoparticles As Doxorubicin Carriers for Effective Anti-Tumor Activity: Preparation and in Vitro Evaluation.

pH/Redox/Lysozyme-Sensitive Hybrid Nanocarriers With Transformable Size for Multistage Drug Delivery

Sub-50 Nm Core-Shell Nanoparticles with the Ph-Responsive Squeezing Release Effect for Targeting Therapy of Hepatocellular Carcinoma.

Two-stage pH-sensitive doxorubicin hydrochloride loaded core–shell nanoparticles with dual drug-loading strategies for the potential anti-tumor treatment

Dual-Responsive Core-Crosslinked Polyphosphoester-Based Nanoparticles for Ph/Redox-Triggered Anticancer Drug Delivery

Phenylboronic Acid-Modified Hollow Silica Nanoparticles for Dual-Responsive Delivery of Doxorubicin for Targeted Tumor Therapy.

pH-controlled delivery of doxorubicin to cancer cells, based on small mesoporous carbon nanospheres.

Ph and Redox Dual Responsive Carrier-Free Anticancer Drug Nanoparticles for Targeted Delivery and Synergistic Therapy

Lipid-Coated CaCO3 Nanoparticles As a Versatile Ph-Responsive Drug Delivery Platform to Enable Combined Chemotherapy of Breast Cancer

Nanoparticles of deoxycholic acid, polyethylene glycol and folic acid-modified chitosan for targeted delivery of doxorubicin

Simply Constructed Chitosan Nanocarriers with Precise Spatiotemporal Control for Efficient Intracellular Drug Delivery

A Ph-Responsive Mesoporous Silica Nanoparticle-Based Drug Delivery System for Targeted Breast Cancer Therapy